Semaglutide 1.34 mg/mL

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, Novo Nordisk A/S

Conditions

Diabetes Mellitus, Type 2Nonalcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis

Phase 1

A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People

CompletedNCT05046873

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2021-09-06End: 2022-01-05Updated: 2023-07-03

A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause

CompletedNCT05153564

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2021-12-13End: 2022-09-01Updated: 2023-11-13

Phase 2

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

CompletedNCT04944992

Merck Sharp & Dohme LLCNonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis

Start: 2021-08-04End: 2022-10-19Updated: 2023-11-15

Related Papers

From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis

Clinical Liver Disease2023-01-132 citations